-
Electronic (PDF)
-
Site License
-
Enterprisewide
Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, February 2012, Pages: 138
Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global melanoma therapeutics market. The report identifies the key trends shaping and driving the global melanoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global melanoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global melanoma therapeutics market was worth $0.8 billion in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 22.8% during 2006–2011. During 2011–2019, the market is expected to record a CAGR of 16.6%, from $0.8 billion in 2011 to $2.6 billion in 2019. The current treatment options for melanoma include -
- Newly approved targeted therapies such as Yervoy(ipilimumab) and Zelboraf(vemurafenib)
- Adjuvant therapies such as Intron-A (interferon alfa-2b) and Sylatron(peg-interferon alfa-2b)
- Immunotherapy such as Proleukin(aldesleukin)
- Cytotoxics such as dacarbazine and other off-label drugs including temozolomide, cisplatin and paclitaxel.
The growth of the market is primarily due to the new product approvals and increase in the incidence rates during the forecast period. Due to these factors, the melanoma therapeutics market is expected to show robust growth until 2019.
Scope
The report provides information on the key drivers and challenges of the melanoma therapeutics market. Its scope includes -
- Annualized revenues data for seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) in the melanoma therapeutics market from 2006-2011 and forecasts for 2011-2019.
- Pipeline analysis data split across the different phases of development, mechanisms of action being developed and emerging trends. Pipeline candidates fall under the major therapeutic classes of immunotherapies, tyrosine kinase inhibitors, microtubule inhibitors, MEK inhibitors, BRAF inhibitors and anti-VEGF monoclonal antibody.
- Analysis of the current and future competition in the global melanoma therapeutics market. The key market players covered are AB Science, Amgen, Bristol-Myers Squibb, Celgene, Eisai, F-Hoffmann-La Roche, GlaxoSmithKline, Plexxikon and vical Incorporated.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet need and implications for the melanoma therapeutics market.
- Analysis of key recent licensing and partnership agreements in the melanoma therapeutics market
Reasons to buy
The report will enhance your decision-making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global melanoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global melanoma therapeutics market landscape? Identify, understand and capitalize.
Keywords
Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China
1
1
1.1 List of Tables
1.2 List of Figures
2 Melanoma Therapeutics - Introduction
2.1 Appearance and Location
2.2 Symptoms
2.2.1 ABCDE System
2.2.2 Other Signs of Melanoma
2.3 Etiology
2.3.1 Environmental Factor
2.3.2 Genetic Mutation
2.4 Pathophysiology
2.5 Risk Factors
2.6 Types of Melanoma
2.7 Epidemiology
2.8 Screening Guidelines for Melanoma
2.9 Diagnosis and Treatment Guidelines for Melanoma
2.10 Diagnosis
2.10.1 Early Detection of Melanoma
2.10.2 Types of Skin Biopsy
2.10.3 Pathology Report
2.10.4 Diagnostic Indicators
2.10.5 Procedures and Tests to Detect Metastases
2.10.6 Other Secondary Tests
2.10.7 Diagnostic Algorithm
2.10.8 Approval of New Diagnostic Devices
2.11 Staging
2.11.1 Stage 0
2.11.2 Stage IA
2.11.3 Stage IIA
2.11.4 Stage IIB
2.11.5 Stage IIC
2.11.6 Stage IIIA
2.11.7 Stage IIIB
2.11.8 Stage IIIC
2.11.9 Stage IV
2.11.10 Broad Staging of Melanoma
2.11.11 Survival Rates by Stage
2.12 Treatment
2.12.1 Surgery
2.12.2 Non-surgical
2.12.3 Treatment by Stage
2.13 GlobalData Pipeline Report Guidance
3 Melanoma Therapeutics - Market Characterization
3.1 Melanoma Therapeutics Market Size (2006-2011) - Global
3.2 Melanoma Therapeutics Market Forecast (2011-2019) - Global
3.3 Melanoma Therapeutics Market Size (2006-2011) - The US
3.4 Melanoma Therapeutics Market Forecast (2011-2019) - The US
3.5 Melanoma Therapeutics Market Size (2006-2011) - The UK
3.6 Melanoma Therapeutics Market Forecast (2011-2019) - The UK
3.7 Melanoma Therapeutics Market Size (2006-2011) - France
3.8 Melanoma Therapeutics Market Forecast (2011-2019) - France
3.9 Melanoma Therapeutics Market Size (2006-2011) - Germany
3.10 Melanoma Therapeutics Market Forecast (2011-2019) - Germany
3.11 Melanoma Therapeutics Market Size (2006-2011) - Italy
3.12 Melanoma Therapeutics Market Forecast (2011-2019) - Italy
3.13 Melanoma Therapeutics Market Size (2006-2011) - Spain
3.14 Melanoma Therapeutics Market Forecast (2011-2019) - Spain
3.15 Melanoma Therapeutics Market Size (2006-2011) - Japan
3.16 Melanoma Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Melanoma Therapeutics Market
3.17.1 Drivers for the Melanoma Therapeutics Market
3.17.2 Barriers for the Melanoma Therapeutics Market
3.18 Opportunity and Unmet Need
3.18.1 Opportunity and Unmet Need for the Metastatic Melanoma Therapeutics Market
3.19 Key Takeaway
4 Melanoma Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.2.1 Competitor Assessment within Different Categories Employed in Melanoma Therapeutics Treatment
4.3 Product Profiles for Recommended Drugs in Melanoma Therapeutics Market
4.3.1 Yervoy (ipilimumab)
4.3.2 Zelboraf (vemurafenib)
4.3.3 Sylatron (peg-interferon alfa-2b)
4.3.4 DTIC-Dome (dacarbazine)
4.3.5 Intron A (high-dose interferon alfa-2b)
4.3.6 Proleukin (aldesleukin or Interleukin-2 or IL-2)
4.3.7 Temodar (temozolomide, Temodal in the UK and Europe)
4.4 Key Takeaway
5 Melanoma Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Melanoma Therapeutics - Pipeline by Phases of Development
5.3.1 Melanoma Therapeutics - Phase III Pipeline
5.3.2 Melanoma Therapeutics - Phase II Pipeline
5.3.3 Melanoma Therapeutics - Phase I/II Pipeline
5.3.4 Melanoma Therapeutics - Phase I Pipeline
5.3.5 Melanoma Therapeutics - Preclinical Pipeline
5.3.6 Melanoma Therapeutics - Discovery Pipeline
5.4 Melanoma Therapeutics- Pipeline by Mechanism of Action
5.5 Pipeline by Line of Therapy
5.5.1 Technology Trends Analytic Framework
5.6 Molecule Profiles of Key Late Stage Drugs under Clinical Development
5.6.1 Abraxane (ABI-007)
5.6.2 Allovectin-7
5.6.3 Avastin (bevacizumab)
5.6.4 Dabrafenib (GSK2118436)
5.6.5 MAGE-A3
5.6.6 Masitinib (AB1010)
5.6.7 OncoVEXGM-CSF (talimogene laherparepvec)
5.6.8 Tasigna (nilotinib)
5.6.9 Trametinib (GSK1120212)
5.7 Key Takeaway
6 Melanoma Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Melanoma Therapeutics Clinical Trials
7 Melanoma Therapeutics - Strategic Assessment
7.1 Melanoma Therapeutics - Implications for Future Market Competition
8 Mlenaoma Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 AB Science
8.2.2 Amgen Inc.
8.2.3 Bristol-Myers Squibb
8.2.4 Celgene Corporation
8.2.5 Eisai Co., Ltd.
8.2.6 F. Hoffmann-La Roche Ltd.
8.2.7 GlaxoSmithKline plc
8.2.8 Novartis AG
8.2.9 Vical Incorporated
9 Licenising and Partnership Deals
10 Melanoma Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Melanoma, Diagnosis and Treatment Guidelines
Table 2: Melanoma Incidence, 2008-2020
Table 3: Screening Guidelines for Early Detection of Melanoma
Table 4: Melanoma, Diagnosis and Treatment Guidelines
Table 5: Melanoma, Principles of Pathology
Table 6: Clark Levels
Table 7: Melanoma TNM System Description
Table 8: Melanoma Anatomic Stage/Prognostic Groups
Table 9: Melanoma, Survival Rate
Table 10: Principles of Surgical Margins for Wide Excision of Primary Melanoma
Table 11: Major Systemic Therapies for Melanoma
Table 12: Cytotoxic Drugs Used for the Treatment of Advanced Melanoma
Table 13: Melanoma Therapeutics Market, Global, Revenue ($bn), 2006-2011
Table 14: Melanoma Therapeutics Market, Global, Forecast ($bn), 2011-2019
Table 15: Melanoma Therapeutics Market, The US, Revenue ($bn), 2006-2011
Table 16: Melanoma Therapeutics Market, The US, Forecast ($bn), 2011-2019
Table 17: Melanoma Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 18: Melanoma Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 19: Melanoma Therapeutics Market, France, Revenue ($m), 2006-2011
Table 20: Melanoma Therapeutics Market, France, Forecast ($m), 2011-2019
Table 21: Melanoma Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 22: Melanoma Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 23: Melanoma Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 24: Melanoma Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 25: Melanoma Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 26: Melanoma Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 27: Melanoma Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 28: Melanoma Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 29: Survival Rates of Yervoy Versus gp100 Arm
Table 30: Severe to Fatal Immune-Mediated Adverse Reactions of Yervoy
Table 31: Severe Adverse Events of Yervoy
Table 32: Efficacy Results of Zelboraf Versus Decarbazine in the BRIM3 Dtudy
Table 33: Adverse Reactions Reported in = 10% of Patients Treated with Zelboraf in the BRIM3 Study
Table 34: Adverse Reactions Reported in = 10% of Patients Treated with Zelboraf in the BRIM2 Study
Table 35: Adverse Reactions Occurring in = 5% of Melanoma Patients
Table 36: Sylatron Dose Modification
Table 37: Intron A Dosage Forms for Malignant Melanoma
Table 38: Efficacy Results of Melanoma
Table 39: Responses of Proleukin
Table 40: Melanoma - Phase III Pipeline
Table 41: Melanoma - Phase II Pipeline
Table 42: Melanoma - Phase I/II Pipeline
Table 43: Melanoma - Phase I Pipeline
Table 44: Melanoma - Preclinical Pipeline
Table 45: Melanoma - Discovery Pipeline
Table 46: Melanoma Therapeutics - Mechanism of Action that Constitute ‘Others’
Table 47: Melanoma Therapeutics, Global, Pipeline by Line of Therapy, 2011
Table 48: Melanoma Therapeutics Market, Global, Clinical Trials by Country, November 2011
Table 49: Melanoma Therapeutics Market, Global, Clinical Trials by Phase, November 2011
Table 50: Melanoma Therapeutics Market, Global, Clinical Trials by Status, November 2011
Table 51: Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, November 2011
Table 52: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Sponsors, November 2011
Table 53: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, November 2011
Table 54: AB Science- Melanoma Pipeline Product, 2012
Table 55: Amgen - Promising Molecules in Pipeline for Melanoma, 2011
Table 56: Bristol-Myers Squibb - Promising Molecules in Pipeline for Melanoma, 2011
Table 57: Celgene Corporation - Melanoma Pipeline Product, 2011
Table 58: Eisai Co., Ltd. - Promising Molecules in Pipeline for Melanoma, 2011
Table 59: F. Hoffmann-La Roche Ltd. - Promising Molecules in Pipeline for Melanoma, 2011
Table 60: GlaxoSmithKline plc- Promising Molecules in Pipeline for Melanoma, 2011
Table 61: Novartis AG - Promising Molecules in Pipeline for Melanoma, 2011
Table 62: Vical Incorporated - Melanoma Pipeline Product, 2012
Table 63: Melanoma , Global Deals , 2009-2011
1.2 List of Figures
Figure 1: Melanoma, Treatment Options
Figure 2: Melanoma Therapeutics Market, Global, Revenue ($bn), 2006-2011
Figure 3: Melanoma Therapeutics, Market Share ($m), 2011
Figure 4: Melanoma Therapeutics Market, Global, Forecast ($bn), 2011-2019
Figure 5: Melanoma Therapeutics Market, Global, Market Share ($m), 2019
Figure 6: Melanoma Therapeutics Market, The US, Revenue ($bn), 2006-2011
Figure 7: Melanoma Therapeutics Market, The US, Forecast ($bn), 2011-2019
Figure 8: Melanoma Market, The UK, Revenue ($m), 2006-2011
Figure 9: Melanoma Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 10: Melanoma Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 11: Melanoma Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 12: Melanoma Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 13: Melanoma Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 14: Melanoma Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 15: Melanoma Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 16: Melanoma Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 17: Melanoma Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 18: Melanoma Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 19: Melanoma Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 20: Melanoma Therapeutics Market, Drivers and Barriers, 2011
Figure 21: Opportunity and Unmet Need for Metastatic Melanoma Therapeutics Market, 2011
Figure 22: Opportunity and Unmet Need for BRAF Mutation Positive Metastatic Melanoma Therapeutics Market, 2011
Figure 23: Melanoma Therapeutics Market - Strategic Competitor Assessment for Metastatic Melanoma, 2011
Figure 24: Melanoma Therapeutics Market - Strategic Competitor Assessment in Adjuvant Setting, 2011
Figure 25: Melanoma Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 26: Melanoma Therapeutics, Global, Pipeline by Mechanism of Action, 2011
Figure 27: Melanoma Therapeutics, Global, Pipeline by Line of Therapy, 2011
Figure 28: Melanoma Therapeutics, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011
Figure 29: Melanoma Therapeutics, Global, Technology Trends Description of Pipeline Drugs, 2011
Figure 30: Melanoma Therapeutics Market, Global, Clinical Trials by Country, November 2011
Figure 31: Melanoma Therapeutics Market, Global, Clinical Trials by Phase, November 2011
Figure 32: Melanoma Therapeutics Market, Global, Clinical Trials by Status, November 2011
Figure 33: Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, November 2011
Figure 34: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Sponsors, November 2011
Figure 35: Melanoma Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, November 2011
Figure 36: Implications for Future Market Competition in Melanoma Therapeutics Market, 2011
Figure 37: Melanoma Therapeutics - Pipeline by Company, 2011
Figure 38: Epidemiology Based Forecasting
Figure 39: Market Forecasting Model
GlobalData, the industry analysis specialist, has released its new report, “Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global melanoma therapeutics market. The report identifies the key trends shaping and driving the global melanoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global melanoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The Melanoma Therapeutics Market is forecast to Show Robust Growth Until 2019
GlobalData estimates that the global melanoma therapeutics market was worth $0.8 billion in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 22.8% during 2006-2011. During 2011-2019, the market is expected to record a CAGR of 16.6%, from $0.8 billion in 2011 to $2.6 billion in 2019. The current treatment options for melanoma include:
• Newly approved targeted therapies such as Yervoy (ipilimumab) and Zelboraf (vemurafenib)
• Adjuvant therapies such as Intron-A (interferon alfa-2b) and Sylatron (peg-interferon alfa-2b)
• Immunotherapy such as Proleukin (aldesleukin)
• Cytotoxics such as dacarbazine and off-label drugs including temozolomide, cisplatin and paclitaxel.
The growth of the market is primarily due to new product approvals and an increase in incidence rates during the forecast period. Due to these factors, the melanoma therapeutics market is expected to show robust growth until 2019.
2011 marked the beginning of a new era for the treatment of melanoma with three new drug approvals after more than a decade. In March 2011, the FDA approved Yervoy in the US for the treatment of unresectable or metastatic melanoma. It received approval in the EU in July 2011 for the treatment of adults with previously-treated advanced melanoma. Zelboraf was approved by the US FDA in August 2011 for the treatment of patients with BRAFV600E mutation-positive inoperable or metastatic melanoma, while the European Medicines Agency recommended the granting of marketing authorization for Zelboraf on December 16, 2011. Sylatron recieved approval in the US in March 2011 for the adjuvant treatment of melanoma.
AB Science
Amgen Inc.
Bristol-Myers Squibb
Celgene Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Novartis AG
Vical Incorporated
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
